AQR Capital Management
AMRX icon

AQR Capital Management’s Amneal Pharmaceuticals AMRX Stock Holding History

AQR Capital Management’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.8M Sell
795,028
-69,764
-8% -$956K ﹤0.01% 1373
2026
Q1 		$10.7M Sell
864,792
-181,320
-17% -$2.43M ﹤0.01% 1307
2025
Q4 		$13.2M Buy
1,046,112
+32,096
+3% +$367K 0.01% 1091
2025
Q3 		$10.2M Sell
1,014,016
-5,089
-0.5% -$45.7K 0.01% 1086
2025
Q2 		$8.24M Buy
1,019,105
+273,630
+37% +$2.06M 0.01% 1050
2025
Q1 		$6.25M Buy
745,475
+408,677
+121% +$3.41M 0.01% 1041
2024
Q4 		$2.67M Buy
336,798
+33,545
+11% +$281K ﹤0.01% 1380
2024
Q3 		$2.52M Sell
303,253
-131,829
-30% -$1.03M ﹤0.01% 1383
2024
Q2 		$2.76M Sell
435,082
-321,305
-42% -$2.04M ﹤0.01% 1312
2024
Q1 		$4.58M Sell
756,387
-72,362
-9% -$408K 0.01% 1017
2023
Q4 		$5.03M Sell
828,749
-110,897
-12% -$494K 0.01% 948
2023
Q3 		$3.97M Sell
939,646
-1,216,596
-56% -$4.54M 0.01% 1018
2023
Q2 		$6.68M Sell
2,156,242
-854,660
-28% -$1.82M 0.01% 787
2023
Q1 		$4.19M Buy
3,010,902
+874,650
+41% +$1.74M 0.01% 971
2022
Q4 		$4.25M Buy
2,136,252
+1,164,091
+120% +$2.61M 0.01% 970
2022
Q3 		$1.96M Buy
972,161
+679,824
+233% +$1.91M ﹤0.01% 1209
2022
Q2 		$930K Buy
292,337
+55,339
+23% +$200K ﹤0.01% 1452
2022
Q1 		$988K Buy
+236,998
New +$1.05M ﹤0.01% 1540
2018
Q3 		– Sell
-41,041
Closed -$673K – 2258
2018
Q2 		$673K Buy
+41,041
New +$720K ﹤0.01% 1875

Other funds holding AMRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

AQR Capital Management's AMRX Position: Q2 2026 in Review

AQR Capital Management reduced its Amneal Pharmaceuticals (AMRX) stake by 8.1% in Q2 2026, selling an estimated $956K and leaving 795,028 shares worth $13.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1373.

AQR Capital Management first reported a position in AMRX in Q2 2018 and has held it in 19 quarters since. 311 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

  • AQR Capital Management held 795,028 shares of Amneal Pharmaceuticals worth $13.8M as of Q2 2026.
  • AQR Capital Management sold 69,764 Amneal Pharmaceuticals shares in Q2 2026, an estimated $956K.
  • Amneal Pharmaceuticals made up ﹤0.01% of AQR Capital Management's portfolio in Q2 2026, its #1373 holding.
  • AQR Capital Management first reported a position in Amneal Pharmaceuticals in Q2 2018 and has held it in 19 quarters since.
  • 311 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.